Vertex Pharmaceuticals | VRTX - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 42.1B 1.19B 2026-03
Acadia Pharmaceuticals USD 305.52M 28.41M 2026-03
Agios Pharmaceuticals USD 58.84M 23.36M 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Amgen USD 24.96B 534M 2026-03
Arrowhead Research USD 295.22M 52.2M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Bristol-Myers Squibb USD 19.16B 4.26B 2026-03
Gilead Sciences USD 9.48B 2.34B 2026-03
Incyte USD 1.49B 25.52M 2026-03
Insmed USD 361.01M 107.87M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
J&J USD 57.72B 3.59B 2026-03
Merck USD 26.94B 1.38B 2026-03
Moderna USD 2.4B 408M 2026-03
Neurocrine Biosciences USD 831.7M 88.3M 2026-03
Novartis USD 31.37B 4.1B 2026-03
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Roche Holding CHF 28B 421M 2025-12
Sangamo BioSciences USD 47.66M 1.9M 2025-06
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
Ultragenyx Pharmaceutical USD 325M 59M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03
Vertex Pharmaceuticals USD 3.88B 19.4M 2026-03